Bloomberg/Businessweek Media Statement


Wednesday, May 24, 2017 8:01 am EDT



Alexion is disappointed that the article published in Businessweek does not fully and accurately reflect the important work of our global employees who are dedicated to transforming the lives of patients with devastating and rare diseases. Alexion has a high-performing, patient-centric culture. Our focus on life-saving therapies informs all that we do, and this will not change.

Alexion would like to make the following points in response to the article:

  • The diseases that Alexion treats are devastating diseases. Soliris is a transformative therapy that is changing the lives of patients with PNH and aHUS, two ultra-rare diseases. Our employees take great pride in providing patients who are confronting life-threatening diseases with the therapies that help them live productive and fulfilling lives. The diagnosis and decision of whether to treat a patient with Soliris is always up to the treating physician.
  • Alexion shares patient-focused objectives with Patient Advocacy Organizations (PAOs) worldwide, including increasing the understanding of rare and ultra-rare diseases, improving patient care, and enhancing patient access to innovative therapies. Like others in the industry, we engage regularly with PAOs in support of these shared objectives. Alexion has policies and procedures that govern our interactions with PAOs and that emphasize the importance of independence between Alexion and the PAOs.
  • Patients with rare diseases often face multi-year delays in getting an accurate diagnosis. As a company that exclusively focuses on serving patients with rare diseases, Alexion believes it has a responsibility to help patients receive a rapid and accurate diagnosis, and its lab partnerships provide valuable insights that inform disease education programs. As common in the industry, Alexion obtains data from labs; the information we receive is blinded and compliant with HIPAA regulations. Alexion is committed to making these agreements transparent and to ensuring that they are compliant with applicable laws, regulations, and industry guidelines.
  • Nurse Case Managers provide essential education, assistance with access, as well as personalized treatment support for patients and their caregivers affected by rare diseases. Alexion recently changed the reporting structure of the nurse case management program in the U.S. to report to Medical Affairs and will also be implementing this change ex-US.

Alexion’s Management team and Board of Directors are focused on building a culture where high-performing teams embrace quality, responsibility, integrity, and ethical behavior. The Company routinely monitors and updates its policies to maintain high ethical standards, and continues to make investments in talent, training, and systems to keep pace with Alexion’s tremendous global growth. We have also made recent changes in people, processes, and governance to strengthen our business practices, as we communicated in our company statement on May 17, 2017.

The fundamentals of our business are strong. As Alexion continues to grow its business, the Company will be anchored by a culture of compliance and driven by a passion and dedication to patients.